350 related articles for article (PubMed ID: 33042138)
1. Costimulation Blockade in Vascularized Composite Allotransplantation.
Giannis D; Moris D; Cendales LC
Front Immunol; 2020; 11():544186. PubMed ID: 33042138
[TBL] [Abstract][Full Text] [Related]
2. Sensitization and Desensitization in Vascularized Composite Allotransplantation.
Moris D; Cendales LC
Front Immunol; 2021; 12():682180. PubMed ID: 34456906
[TBL] [Abstract][Full Text] [Related]
3. De novo belatacept in clinical vascularized composite allotransplantation.
Cendales LC; Ruch DS; Cardones AR; Potter G; Dooley J; Dore D; Orr J; Ruskin G; Song M; Chen DF; Selim MA; Kirk AD
Am J Transplant; 2018 Jul; 18(7):1804-1809. PubMed ID: 29723921
[TBL] [Abstract][Full Text] [Related]
4. The role of B cell immunity in VCA graft rejection and acceptance.
Kaufman CL; Cascalho M; Ozyurekoglu T; Jones CM; Ramirez A; Roberts T; Tien HY; Moreno R; Galvis E; Tsai TM; Palazzo M; Farner S; Platt JL
Hum Immunol; 2019 Jun; 80(6):385-392. PubMed ID: 30836129
[TBL] [Abstract][Full Text] [Related]
5. Upper extremity and craniofacial vascularized composite allotransplantation: ethics and immunosuppression.
Benedict J; Magill G
Emerg Top Life Sci; 2019 Nov; 3(6):681-686. PubMed ID: 32915212
[TBL] [Abstract][Full Text] [Related]
6. Adipose-derived stromal cell therapy combined with a short course nonmyeloablative conditioning promotes long-term graft tolerance in vascularized composite allotransplantation.
Schweizer R; Taddeo A; Waldner M; Klein HJ; Fuchs N; Kamat P; Targosinski S; Barth AA; Drach MC; Gorantla VS; Cinelli P; Plock JA
Am J Transplant; 2020 May; 20(5):1272-1284. PubMed ID: 31774619
[TBL] [Abstract][Full Text] [Related]
7. Th17 cell inhibition in a costimulation blockade-based regimen for vascularized composite allotransplantation using a nonhuman primate model.
Atia A; Moris D; McRae M; Song M; Stempora L; Leopardi F; Williams K; Kwun J; Parker W; Cardones AR; Kirk AD; Cendales LC
Transpl Int; 2020 Oct; 33(10):1294-1301. PubMed ID: 32277724
[TBL] [Abstract][Full Text] [Related]
8. Large Animal Models of Vascularized Composite Allotransplantation: A Review of Immune Strategies to Improve Allograft Outcomes.
Matar AJ; Crepeau RL; Mundinger GS; Cetrulo CL; Torabi R
Front Immunol; 2021; 12():664577. PubMed ID: 34276656
[TBL] [Abstract][Full Text] [Related]
9. De novo donor-specific HLA antibodies after combined intestinal and vascularized composite allotransplantation - a retrospective study.
Weissenbacher A; Vrakas G; Chen M; Reddy S; Allan P; Giele H; Barnardo MCNM; Vaidya A; Friend PJ; Fuggle SV
Transpl Int; 2018 Apr; 31(4):398-407. PubMed ID: 29150964
[TBL] [Abstract][Full Text] [Related]
10. Cellular activation pathways and interaction networks in vascularized composite allotransplantation.
Knoedler L; Knoedler S; Panayi AC; Lee CAA; Sadigh S; Huelsboemer L; Stoegner VA; Schroeter A; Kern B; Mookerjee V; Lian CG; Tullius SG; Murphy GF; Pomahac B; Kauke-Navarro M
Front Immunol; 2023; 14():1179355. PubMed ID: 37266446
[TBL] [Abstract][Full Text] [Related]
11. Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration.
Kueckelhaus M; Fischer S; Seyda M; Bueno EM; Aycart MA; Alhefzi M; ElKhal A; Pomahac B; Tullius SG
Transpl Int; 2016 Jun; 29(6):655-62. PubMed ID: 26265179
[TBL] [Abstract][Full Text] [Related]
12. Monitoring and long-term outcomes in vascularized composite allotransplantation.
Kaufman CL; Ouseph R; Marvin MR; Manon-Matos Y; Blair B; Kutz JE
Curr Opin Organ Transplant; 2013 Dec; 18(6):652-8. PubMed ID: 24220047
[TBL] [Abstract][Full Text] [Related]
13. Composite tissue allotransplantation: opportunities and challenges.
Iske J; Nian Y; Maenosono R; Maurer M; Sauer IM; Tullius SG
Cell Mol Immunol; 2019 Apr; 16(4):343-349. PubMed ID: 30842628
[TBL] [Abstract][Full Text] [Related]
14. Cell therapy in vascularized composite allotransplantation.
Anggelia MR; Cheng HY; Lai PC; Hsieh YH; Lin CH; Lin CH
Biomed J; 2022 Jun; 45(3):454-464. PubMed ID: 35042019
[TBL] [Abstract][Full Text] [Related]
15. A local drug delivery system prolongs graft survival by dampening T cell infiltration and neutrophil extracellular trap formation in vascularized composite allografts.
Arenas Hoyos I; Helmer A; Yerly A; Lese I; Hirsiger S; Zhang L; Casoni D; Garcia L; Petrucci M; Hammer SE; Duckova T; Banz Y; Montani M; Constantinescu M; Vögelin E; Bordon G; Aleandri S; Prost JC; Taddeo A; Luciani P; Rieben R; Sorvillo N; Olariu R
Front Immunol; 2024; 15():1387945. PubMed ID: 38887281
[TBL] [Abstract][Full Text] [Related]
16. Vascularized composite allograft-specific characteristics of immune responses.
Issa F
Transpl Int; 2016 Jun; 29(6):672-81. PubMed ID: 26927941
[TBL] [Abstract][Full Text] [Related]
17. Spontaneous resolution of acute rejection and tolerance induction with IL-2 fusion protein in vascularized composite allotransplantation.
Jindal R; Unadkat J; Zhang W; Zhang D; Ng TW; Wang Y; Jiang J; Lakkis F; Rubin P; Lee WP; Gorantla VS; Zheng XX
Am J Transplant; 2015 May; 15(5):1231-40. PubMed ID: 25676865
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Review of the Reported Complications Related to Facial and Upper Extremity Vascularized Composite Allotransplantation.
Milek D; Reed LT; Echternacht SR; Shanmugarajah K; Cetrulo CL; Lellouch AG; Langstein HN; Leckenby JI
J Surg Res; 2023 Jan; 281():164-175. PubMed ID: 36162189
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppression maintenance in vascularized composite allotransplantation: what is just right?
Howsare M; Jones CM; Ramirez AM
Curr Opin Organ Transplant; 2017 Oct; 22(5):463-469. PubMed ID: 28759463
[TBL] [Abstract][Full Text] [Related]
20. Novel Strategies in Transplantation: Genetic Engineering and Vascularized Composite Allotransplantation.
Kauke-Navarro M; Noel OF; Knoedler L; Knoedler S; Panayi AC; Stoegner VA; Huelsboemer L; Pomahac B
J Surg Res; 2023 Nov; 291():176-186. PubMed ID: 37429217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
